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Identity 
Other names: MGC12557; my036; p29ING4 
HGNC (Hugo): ING4 
Location: 12p13.31 
DNA/RNA 
Description 
ING4 belongs to family of highly homologous five 
members containing PHD domain and has been 
identified through a computational sequence  
homology search for expressed tag clones with a PHD 
finger motif (Shiseki et al., 2003). ING4 gene is located 
on chromosome 12p13.31 and consists of eight exons 
encoding a 29-kDa protein expressed in multiple 
human tissues. 
Transcription 
Multiple alternatively spliced transcript variants have 
been observed using different splice sites in the coding 
region; transcript variants span from 1461 bp to 1313 
bp. 
Wobble splicing events have been described at exon 4 
and 5 boundary. 
 
Figure adapted from Atlas of Genetics and Cytogenetics in Oncology and Haematology. 
ING4 (inhibitor of growth family, member 4) Greco A, Miranda C 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2011; 15(8)  621 
Different splicing variants have been identified (among 
them -v1, -v2, -v3 and -v4/∆4AA) involving 12 bp 
(379-390) and resulting in in frame deletions of one to 
four aminoacids in NLS (Tsai and Lin, 2006). 
Several splicing variants have been described lacking 
exon 2, 3 and 6 (entirely or in part), and named ING4-
∆Ex2, -∆Ex3, -∆Ex6A and -∆Ex6B, respectively (Raho 
et al., 2007). 
Splicing variants have been detected in all tissues 
analysed, indicating that are not tissue specific (Tsai 
and Lin, 2006; Raho et al., 2007). 
More recently five novel spliced variants of ING4-v1 
and -v2 were identified, causing codon frame shift and 
eventually deletion of NLS or PHD domains. Increased 
expression of these variants was found in gastric 
adenocarcinomas compared to normal tissue (Li M et 
al., 2009). 
Protein 
Note 
249 aminoacids, 29 kDa protein. 
Description 
ING4 protein contains several conserved regions: i) a 
leucine zipper-like (LZL) domain, probably involved in 
protein interactions, located at the N-terminus; ii) a 
functional bipartite nuclear localization signal (NLS1); 
iii) a C-terminal plant homeo-domain (PHD), a Cys4-
His-Cys3 zinc finger motif spanning 50-80 residues, 
found in many nuclear proteins, such as transcription 
factors and proteins regulating chromatin structure; iv) 
a non functional NLS located at the C-terminal end. 
Expression 
Ubiquitous. 
Localisation 
p29ING4 is a nuclear protein. It possesses a bipartite 
nuclear localization signal. ING4 splicing variants have 
been described involving the NLS1 domain; most/all of 
them retains nuclear localization. Furthermore ING4-v1 
is translocated to the nucleolus and such subcellular 
localization is modulated by two wobble-splicing 
events at the exon 4-5 boundary, causing displacement 
from the nucleolus to the nucleus. 
Function 
ING4 was also isolated through a screening for genes 
able to suppress loss of contact inhibition, thus 
suggesting its tumor suppressor role. 
ING4 is a nuclear protein participating to a variety of 
cellular functions, such as apoptosis, cell-cycle  
regulation, chromatin remodeling, and regulation of 
gene expression. Several ING4 partners have been 
described. Similarly to the other ING members, ING4 
was described to interact with p53 and to modulate p53 
transcriptional activity (Shiseki et al., 2003). The 
interaction of ING4 with p53 is mediated by the 
bipartite ING4 nuclear localization signal (NLS) 
(Zhang et al., 2005) and drives an increase of p53 
acetylation at lysine 382 (Shiseki et al., 2003). ING4 is 
a critical regulator of chromatin acetylation required for 
gene expression. In particular, ING4 associates with the 
HAT complex HBO1 and it is required for the majority 
of histone 4 acetylation and for normal progression 
through S phase (Doyon et al., 2006; Shi et al., 2006). 
Recently a critical role for specific recognition of 
histone H3 trimethylated at lysine 4 (H3K4me3) by the 
ING4 PHD finger in mediating ING4 gene expression 
and tumor suppressor functions has been shown (Hung 
et al., 2009). 
ING4 can also function as repressor of factors 
mediating angiogenesis. It was demonstrated that ING4 
plays an inhibitory role on NF-kappaB activity by 
interaction with p65NF-kappaB and that the lack of 
inhibition of the NF-kappaB pathway by ING4 results 
in increased angiogenesis in glioblastomas (Garkavtsev 
et al., 2004). More recently, it has been described that 
physiologic levels of ING4 govern innate immunity in 
mice by regulating the levels of IkappaB and NF-
kappaB proteins and the activation of select cytokine 
promoters (Coles et al., 2010). 
ING4 was also described to repress the ability of 
hypoxia inducible factor (HIF)-1 to activate 
transcription of its downstream target genes by 
interacting with the HPH-2 prolyl hydroxylase. Under 
hypoxic conditions, ING4 may act as an adapter protein 
recruiting transcriptional repressors to mediate HIF 
activity (Ozer et al., 2005). 
Involvement of ING4 in regulation of apoptosis has 
been demonstrated in several cellular systems. Its 
overexpression can induce apoptosis through the 
downregulation of Bcl-2 and the upregulation of p21 
and Bax expression (Shiseki et al., 2003; Yu et al., 
2007; Li X et al., 2009b; Cai et al., 2009). 
Homology 
ING4 protein shares homology with other ING family 
members with respect to the following regions: i) a 
leucine zipper-like (LZL) domain, probably involved in 
interaction with proteins, located at the N-terminus of 
all the ING proteins except for ING1; ii) a nuclear 
localization signal (NLS); iii) a C-terminal plant 
homeo-domain (PHD) involved in chromatin. 
 
LZL: leucine zipper-like; NLS1: nuclear localization signal 1; PHD: plant homology domain; NLS2: nuclear localization signal 2. 
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Mutations 
Note 
The following ING4 point mutations have been found 
in lung adenocarcinoma and small cell lung carcinoma 
(H23 and H28, respectively) human cancer cell lines. 
N214D: it alters ING4 capability of inhibition of 
proliferation, anchorage independent cell migration 
reducing protein stability by proteasome mediated 
degradation. 
Y121N: it does not alter ING4 functions (Moreno et al., 
2010). 
Implicated in 
Breast cancer 
Cytogenetics 
Analysis of CGH data revealed that 10-20% of primary 
breast tumors present deletions in 12p13. The deletions 
appear to affect only one copy of the gene; no genomic 
mutations were found in the remaining allele of ING4 
(Kim et al., 2004). 
Head and neck squamous cell 
carcinoma (HNSCC) 
Cytogenetics 
LOH of 12p13. 
Oncogenesis 
Loss of heterozygosity at 12p12-13 region was found in 
66% (33/50) of head and neck squamous cell 
carcinomas by using six highly polymorphic 
microsatellite markers. No mutations of the ING4 gene 
were found. 
Quantitative real-time RT-PCR analysis demonstrated 
decreased expression of ING4 mRNA in 76% of 
primary tumors compared to matched normal samples 
(Gunduz et al., 2005). 
Glioma 
Oncogenesis 
Expression of ING4 is significantly reduced in gliomas 
as compared with normal human brain tissue, and the 
extent of reduction correlates with the progression from 
lower to higher grades of tumours. ING4 regulates 
brain tumour angiogenesis through transcriptional 
repression of NF-kB-responsive genes (Garkavtsev et 
al., 2004). 
Astrocytoma 
Prognosis 
A potential of role of ING4 as a biomarker for the 
prediction of the grade of astrocytic neoplasms has 
been suggested (Klironomos et al., 2010). 
Oncogenesis 
Significantly reduced levels of ING4 were observed in 
human astrocytomas compared to normal brain tissue, 
suggesting that down-regulation of this protein might 
be involved in the pathogenesis of human astrocytic  
tumors. Decreased ING4 expression correlated 
significantly with tumor progression, with lower 
expression levels of ING4 observed in cases of high-
grade neoplasms. A statistical significant negative 
correlation between expression of ING4 and expression 
of nuclear p65 was noticed (Klironomos et al., 2010). 
Hepatocellular carcinoma (HCC) 
Prognosis 
Survival and metastasis analysis indicated that HCC 
patients with lower ING4 expression had poorer overall 
and disease-free survival than those with high 
expression. Multivariable Cox regression analysis 
revealed that the ING4 expression level was an 
independent factor for prognosis (Fang et al., 2009). 
Oncogenesis 
The ING4 mRNA and protein levels were significantly 
lower in HCC than paracarcinomatous liver tissue. 
ING4 expression level correlates with prognosis and 
metastatic potential, suggesting that ING4 as a 
candidate prognostic marker of HCC (Fang et al., 
2009). 
Multiple myeloma (MM) 
Prognosis 
MM patients with high IL-8 production and 
microvascular density (MVD) have significantly lower 
ING4 levels compared with those with low IL-8 and 
MVD. 
Oncogenesis 
ING4 suppression in MM cells up-regulated IL-8 and 
OPN under hypoxic conditions, increasing the hypoxia 
inducible factor-1alpha (HIF-1alpha) activity and its 
target gene NIP-3 expression. ING4 suppression in 
MM cells significantly increased vessel formation in 
vitro, blunted by blocking IL-8 or OPN (Colla et al., 
2007). 
Lung cancer 
Oncogenesis 
Reduced ING4 nuclear and cytoplasmic expression 
were both revealed in lung cancer and associated with 
tumour grade. ING4 expression in the cytoplasm was 
found higher than in the nucleus in a high percentage of 
tumors. Nuclear ING4 inhibition correlated with the 
tumour stage and lymph node metastasis, thus 
suggesting that ING4 is involved in the initiation and 
progression of lung cancers (Wang et al., 2010). 
Gastric cancer 
Oncogenesis 
ING4 RNA and protein were drastically reduced in 
stomach adenocarcinoma cell lines and tissues, 
significantly less in female than male patients. Novel 
spliced forms of ING4-v1 and -v2 were identified in 
both normal and tumor tissue; increased expression of 
the novel spliced variants was observed in tumors; 
however no correlation with clinical parameters was 
observed (Li M et al., 2009). 
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